Antipsychotic-like properties of 5-α-reductase inhibitors

Neuropsychopharmacology

Volumn 33, Issue 13, 2008, Pages 3146-3156

  Bortolato, Marco ^a   Frau, Roberto ^a   Orrù, Marco ^a   Bourov, Youri ^a   Marrosu, Francesco ^a   Mereu, Giampaolo ^a   Devoto, Paola ^a   Gessa, Gian L ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

5 reductase; Apomorphine; Finasteride; Prepulse inhibition of the startle; Schizophrenia; Stereotyped behavior

Indexed keywords

APOMORPHINE; CLOZAPINE; DEXAMPHETAMINE; DIZOCILPINE; DUTASTERIDE; FINASTERIDE; HALOPERIDOL; SKF 105111; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; STEREOTYPY; STEROIDOGENESIS;

ANDROSTANES; ANIMALS; ANTIPSYCHOTIC AGENTS; AZASTEROIDS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; FINASTERIDE; GONADAL STEROID HORMONES; HYPERKINESIS; MALE; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SENSORY GATING; STEREOTYPED BEHAVIOR; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 57349181453     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.39     Document Type: Article

References (82)

1. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH (2006). Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 84: 405-410.
2. Bakshi VP, Swerdlow NR, Geyer MA (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794.
3. Barbaccia ML, Serra M, Purdy RH, Biggio G (2001). Stress and neuroactive steroids. Int Rev Neurobiol 46: 243-272.
4. Barrot M, Vallee M, Gingras MA, Le Moal M, Mayo W, Piazza PV (1999). The neurosteroid pregnenolone sulphate increases dopamine release and the dopaminergic response to morphine in the rat nucleus accumbens. Eur J Neurosci 11: 3757-3760.
5. Beatty WW, Dodge AM, Traylor KL (1982). Stereotyped behavior elicited by amphetamine in the rat: influences of the testes. Pharmacol Biochem Behav 16: 565-568.
6. Bitar MS, Ota M, Linnoila M, Shapiro BH (1991). Modification of gonadectomy-induced increases in brain monoamine metabolism by steroid hormones in male and female rats. Psychoneuroendocrinology 16: 547-557.
7. Bortolato M, Aru GN, Frau R, Orru M, Fa M, Manunta M et al (2005). Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 57: 1550-1558.
8. Bortolato M, Muroni A, Marrosu F (2007). Treatment of Tourette's syndrome with finasteride: a case report. Am J Psychiatry 164: 1914-1915.
9. Bower WH, Altschule MD (1956). Use of progesterone in the treatment of postpartum psychosis. N Engl J Med 254: 157-160.
10. Braff DL, Geyer MA (1990). Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatr 47: 181-188.
11. Breedlove SM (1992). Sexual differentiation of the brain and behavior. In: JB Becker, SM Breedlove, D Crews (eds). Behavioral Endocrinology, MIT Press: Cambridge, MA. pp 39-90.
12. Burki HR (1979). Extrapyramidal side-effects. Pharmacol Ther [B] 5: 525-534.
13. Cabrera RJ, Bregonzio C, Laconi M, Mampel A (2002). Allopregnanolone increase in striatal N-methyl-D-aspartic acid evoked [3H]dopamine release is estrogen and progesterone dependent. Cell Mol Neurobiol 22: 445-454.
14. Castle D, Sham P, Murray R (1998). Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res 33: 179-183.
15. Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M et al (1998). Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 95: 13284-13289.
16. Costall B, Domeney AM, Naylor RJ, Tyers MB (1987). Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92: 881-894.
17. Costall B, Naylor RJ (1995). Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol 116: 2989-2999.
18. Dazzi L, Serra M, Vacca G, Ladu S, Latrofa A, Trapani G et al (2002). Depletion of cortical allopregnanolone potentiates stressinduced increase in cortical dopamine output. Brain Res 932: 135-139.
19. Dazzi L, Seu E, Cherchi G, Barbieri PP, Matzeu A, Biggio G (2007). Estrous cycle-dependent changes in basal and ethanol-induced activity of cortical dopaminergic neurons in the rat. Neuropsychopharmacology 32: 892-901.
20. Dluzen DE, Green MA, Ramirez VD (1986). The effect of hormonal condition on dose-dependent amphetamine-stimulated behaviors in the male rat. Horm Behav 20: 1-6.
21. Ellenbroek BA, Peeters BW, Honig WM, Cools AR (1987). The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl) 93: 343-348.
22. Engel J, Ahlenius S, Almgren O, Carlsson A, Larsson K, Sodersten P (1979). Effects of gonadectomy and hormone replacement on brain monoamine synthesis in male rats. Pharmacol Biochem Behav 10: 149-154.
23. Evenden JL, Robbins TW (1983). Increased response switching, perseveration and perseverative switching following d-amphetamine in the rat. Psychopharmacology (Berl) 80: 67-73.
24. Fabre-Nys C (1998). Steroid control of monoamines in relation to sexual behaviour. Rev Reprod 3: 31-41.
25. Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE et al (2006). A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 12: 53-76.
26. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156: 117-154.
27. Giuliani D, Ferrari F (1997). Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. Physiol Behav 61: 563-567.
28. Goyal RO, Sagar R, Ammini AC, Khurana ML, Alias AG (2004). Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann N Y Acad Sci 1032: 291-294.
29. Grigoriadis S, Seeman MV (2002). The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 47: 437-442.
30. Heinlein CA, Chang C (2002). The roles of androgen receptors and androgenbinding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187.
31. Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C (2000). Gender and bipolar illness. J Clin Psychiatry 61: 393-396; quiz 397.
32. Hernandez L, Gonzalez L, Murzi E, Paez X, Gottberg E, Baptista T (1994). Testosterone modulates mesolimbic dopaminergic activity in male rats. Neurosci Lett 171: 172-174.
33. Hoffman DC, Donovan H, Cassella JV (1993). The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berl) 111: 339-344.
34. Holt DA, Levy MA, Oh HJ, Erb JM, Heaslip JI, Brandt M et al (1990). Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids. J Med Chem 33: 943-950.
35. Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM (2004). Pathways to schizophrenia: the impact of environmental factors. Int J Neuropsychopharmacol 7: S7-S13.
36. Huber TJ, Tettenborn C, Leifke E, Emrich HM (2005). Sex hormones in psychotic men. Psychoneuroendocrinology 30: 111-114.
37. Iversen SD, Creese I (1975). Behavioral correlates of dopaminergic supersensitivity. Adv Neurol 9: 81-92.
38. Jaworska-Feil L, Budziszewska B, Leskiewicz M, Lason W (1998). Opposite effects of inhibitory and excitatory neurosteroids on [3H]dopamine release from rat nucleus accumbens. Pol J Pharmacol 50: 449-452.
39. Kawa I, Carter JD, Joyce PR, Doughty CJ, Frampton CM, Wells JE et al (2005). Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord 7: 119-125.
40. Khisti RT, Deshpande LS, Chopde CT (2002). The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopaminemediated behavior in rodents. Psychopharmacology (Berl) 161: 120-128.
41. Koethe D, Bortolato M, Piomelli D, Leweke FM (2008). Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report. Pharmacopsychiatry (in press).
42. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA (1999). Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 288: 679-684.
43. Leckman JF, Scahill L (1990). Possible exacerbation of tics by androgenic steroids. N Engl J Med 322: 1674.
44. Leung A, Chue P (2000). Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 401: 3-38.
45. Macdonald S, Halliday J, MacEwen T, Sharkey V, Farrington S, Wall S et al (2003). Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry 182: 50-56.
46. Martini L, Celotti F, Melcangi RC (1996). Testosterone and progesterone metabolism in the central nervous system: cellular localization and mechanism of control of the enzymes involved. Cell Mol Neurobiol 16: 271-282.
47. Martini L, Melcangi RC, Maggi R (1993). Androgen and progesterone metabolism in the central and peripheral nervous system. J Steroid Biochem Mol Biol 47: 195-205.
48. Menniti FS, Baum MJ (1981). Differential effects of estrogen and androgen on locomotor activity induced in castrated male rats by amphetamine, a novel environment, or apomorphine. Brain Res 216: 89-107.
49. Monnet FP, Mahe V, Robel P, Baulieu EE (1995). Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 92: 3774-3778.
50. Monnet FP, Maurice T (2006). The sigma1 protein as a target for the nongenomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci 100: 93-118.
51. Palermo-Neto J, Dorce VA (1990). Influences of estrogen and/or progesterone on some dopamine related behavior in rats. Gen Pharmacol 21: 83-87.
52. Pauls DL, Pakstis AJ, Kurlan R, Kidd KK, Leckman JF, Cohen DJ et al (1990). Segregation and linkage analyses of Tourette's syndrome and related disorders. J Am Acad Child Adolesc Psychiatry 29: 195-203.
53. Petitclerc M, Bedard PJ, Di Paolo T (1995). Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog Neuropsychopharmacol Biol Psychiatry 19: 491-497.
54. Poletti A, Coscarella A, Negri-Cesi P, Colciago A, Celotti F, Martini L (1998). 5 alpha-reductase isozymes in the central nervous system. Steroids 63: 246-251.
55. Pope Jr HG, Kouri EM, Hudson JI (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 57: 133-140; discussion 155-136.
56. Randrup A, Munkvad I (1974). Pharmacology and physiology of stereotyped behavior. J Psychiatr Res 11: 1-10.
57. Reddy DS, Kim HY, Rogawski MA (2001). Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 42: 328-336.
58. Reddy DS, Rogawski MA (2002). Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci 22: 3795-3805.
59. Riecher-Rossler A (2002). Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Arch Womens Ment Health 5: 111-118.
60. Rittmaster RS, Antonian L, New MI, Stoner E (1994). Effect of finasteride on adrenal steroidogenesis in men. J Androl 15: 298-301.
61. Romieu P, Martin-Fardon R, Bowen WD, Maurice T (2003). Sigma 1 receptorrelated neuroactive steroids modulate cocaine-induced reward. J Neurosci 23: 3572-3576.
62. Rouge-Pont F, Mayo W, Marinelli M, Gingras M, Le Moal M, Piazza PV (2002). The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. Eur J Neurosci 16: 169-173.
63. Rupprecht R, Koch M, Montkowski A, Lancel M, Faulhaber J, Harting J et al (1999). Assessment of neuroleptic-like properties of progesterone. Psychopharmacology (Berl) 143: 29-38.
64. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988). The catalepsy test: its ups and downs. Behav Neurosci 102: 748-759.
65. Savageau MM, Beatty WW (1981). Gonadectomy and sex differences in the behavioral responses to amphetamine and apomorphine of rats. Pharmacol Biochem Behav 14: 17-21.
66. Segraves RT (1989). Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 46: 275-284.
67. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T (2002). Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 58: 69-74.
68. Strous RD (2005). Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essent Psychopharmacol 6: 141-147.
69. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M et al (2003). Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60: 133-141.
70. Swerdlow NR, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P et al (2000). Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci 20: 4325-4336.
71. Taherianfard M, Shariaty M (2004). Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci 58: 3-9.
72. Thigpen AE, Russell DW (1992). Four-amino acid segment in steroid 5 alphareductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 267: 8577-8583.
73. Torres JM, Ortega E (2003). Differential regulation of steroid 5alpha-reductase isozymes expression by androgens in the adult rat brain. FASEB J 17: 1428-1433.
74. Trenton AJ, Currier GW (2005). Behavioural manifestations of anabolic steroid use. CNS Drugs 19: 571-595.
75. Uygur MC, Arik AI, Altu∂ U, Erol D (1998). Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 63: 208-213.
76. Van den Buuse M, Eikelis N (2001). Estrogen increases prepulse inhibition of acoustic startle in rats. Eur J Pharmacol 425: 33-41.
77. Wada K, Yamada N, Sato T, Suzuki H, Miki M, Lee Y et al (2001). Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics 42: 461-466.
78. Wang Z, Haracz JL, Rebec GV (1992). BMY-14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single unit activity in freely moving rats. Synapse 12: 312-321.
79. Weiss EL, Bowers Jr MB, Mazure CM (1999). Testosterone-patch-induced psychotic mania. Am J Psychiatry 156: 969.
80. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L et al (2003). PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 61: 579-584.
81. Wetzel CH, Hermann B, Behl C, Pestel E, Rammes G, Zieglgansberger W et al (1998). Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 12: 1441-1451.
82. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD (1996). The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol 78: 379-384.